PTC Therapeutics | PTCT - Operating Expenses


PTC Therapeutics reported $226.66M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Cytokinetics USD 200.58M 4.46M Mar/2026
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 23.52B 18.55B Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
TG Therapeutics USD 170.12M 28.04M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026
Xencor USD 82.38M 513K Mar/2026